U.S. stock market midday update: GridAI Tech's stock price surged 16.92%, trading volume skyrocketed, and sector trends have attracted market attention?

U.S. Stock Market Midday Update GridAI Tech, up 16.92%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Regeneron Pharmaceuticals is up 1.70%. Based on recent key news: On December 10, two vice presidents of Regeneron Pharmaceuticals submitted reports on share changes, indicating they repurchased some shares from the company to cover option exercise costs and tax burdens. This news may have affected market confidence in the company's internal management, leading to a rise in stock price. On December 11, Evan Seigerman, an analyst at BMO Capital, maintained a buy rating on Regeneron Pharmaceuticals and set a target price of $850. The analyst's positive rating may have boosted investor confidence in the stock, driving the price up. On December 11, analysts from Scotiabank and Wells Fargo maintained hold ratings on Regeneron Pharmaceuticals, although HSBC maintained a buy rating. These ratings reflect differing market views on the company, which may lead to stock price fluctuations. The pharmaceutical industry has shown stable performance recently, with noticeable capital inflows. AbbVie is down 0.54%. Based on recent key news: On December 10, HSBC upgraded AbbVie’s rating to buy and raised the target price to $265. This upgrade reflects market confidence in AbbVie's future growth potential, pushing the stock price up. On December 11, AbbVie was listed as one of the 15 best stocks for long-term investment, further enhancing investor expectations for stable returns, supporting stock performance. On December 11, analysts pointed out that a strong economy and potential Federal Reserve rate cuts could provide tailwinds for dividend stocks, with AbbVie benefiting as a high-dividend stock, attracting more investor attention. The macroeconomic environment is favorable for dividend stocks, but risks should be noted. Amgen is up 1.30%. Based on recent key news: On December 11, Wells Fargo raised Amgen's target price from $300 to $325, maintaining a "hold" rating. This move reflects market confidence in Amgen's future performance, driving the stock price up. On December 10, Amgen announced a 5.9% increase in its quarterly dividend to $2.52 per share, resulting in an annual yield of 3.2%. This news enhanced investor confidence in the company's financial stability, promoting a rise in stock price. On December 10, Amgen announced a $900 million investment in Ohio to promote local economic development and create jobs. This move demonstrates the company's proactive attitude toward business expansion, further boosting market sentiment. The pharmaceutical industry has shown strong performance recently, with noticeable capital inflows. Stocks with High Market Capitalization in the Industry Gilead Sciences rose by 1.83%. Based on recent key news: On December 11, Wells Fargo analyst Mohit Bansal maintained a buy rating on Gilead Sciences with a target price of $150. This move boosted market confidence in the stock, driving the share price up. On December 10, HSBC raised the target price for Gilead Sciences from $110 to $133. The increase in target price reflects the market's optimistic expectations for the company's future growth, further supporting the upward movement of the stock price. On December 9, TR | OpenAI – 4o’s Veda Pharmyne also gave Gilead Sciences a buy rating, further solidifying the market's positive outlook on the stock. The pharmaceutical industry has performed strongly recently, with significant capital inflows